上市捷报丨沙利文祝贺苏州近岸蛋白质科技股份有限公司成功登陆科创板(688137.SH)

Suzhou Coastal Protein Technology Co., Ltd. (Stock Code:688137.SH) on2022year9month29Successfully logged into the Sci-Tech Innovation Board on the same day. The company is a high-tech enterprise focusing on recombinant protein application solutions. The products and services provided can be applied to biopharmaceuticals, basic life science research, in vitro diagnostics,mRNAFrost & Sullivan, in many areas such as vaccine drugsFrost & SullivanFrost & Sullivan, hereinafter referred to as 'Frost & Sullivan', hereby warmly congratulates the company on its successful listing.

Suzhou Coastal Protein Technology Co., Ltd. (hereinafter referred to as 'Coastal Protein') was established on2022year9month29The company was successfully listed on the stock market, with the number of shares issued being1,754.386010,000 shares, issue price per share106.19yuan.

The company is a high-tech enterprise focusing on recombinant protein application solutions. Its main business includes the research, development, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, as well as providing related technical services. As an upstream supplier in the fields of healthcare and life sciences, the company is committed to providing timely, stable, and high-quality products and services to downstream customers, helping global biopharmaceutical enterprises and research institutions innovate and upgrade their technologies and products. The company has established comprehensive technology platforms for protein research and development technology, antibody development, enzyme molecular evolution technology, and in the fields of protein applications such as diagnostics, vaccines, and drugs, enabling innovation support from raw material to applied technology development across the entire industrial chain. Frost & Sullivan has long been paying attention to the global and Chinese biopharmaceutical industries, publishing a large number of research reports that are widely cited in the prospectuses of leading science and technology innovation board listed companies in the industry, helping customers accelerate growth.

Overview of the Recombinant Protein Market

With the booming development of the domestic biopharmaceutical industry and the impact of the COVID-19 pandemic, the recombinant protein market has shown strong momentum. The scale of the Chinese recombinant protein market has grown from2015year51RMB 10 billion grew to2020year145.4100 billion RMB, with an annual compound growth rate during that period23.3%estimated2025The annual market scale will reach337.71000 million RMB2020Year to2025The annual compound growth rate for the year is close to18.4%.

Market Scale and Forecast of Recombinant Proteins in China

Data source: Analysis by Frost & Sullivan

Overview of the Recombinant Protein Biology Research Reagent Market

With the development of scientific research, biopharmaceutical industry, and the rise of precision medicine, research institutions and pharmaceutical companies have significantly increased their requirements for the quality of recombinant proteins, preferring more stable and mature high-quality recombinant proteins to reduce the failure rate of drug research and development and production. Therefore, the demand for recombinant protein products will change accordingly with the development of downstream biopharmaceutical R&D, diagnostics, and new vaccines markets. Recombinant protein raw material companies with high product quality and strong brand influence will be more competitive in future market competition, gain market recognition, and achieve sustainable development. In China, the overall market for recombinant protein biological research reagents2015year4.2RMB 10 billion grew to2020year11.4100 billion RMB, with an annual compound growth rate during that period22.1%estimated2025The annual market scale will reach25.41000 million RMB2020Year-end2025The annual compound growth rate for the year17.4%.

Market Scale and Forecast of Recombinant Protein Bio-research Reagents in China

2015Year to2025Year (estimated)

Data source: Analysis by Frost & Sullivan

Overview of the In Vitro Diagnostic Reagent Raw Materials Market

our countryIVDThe overall rapid development of the industry has driven synchronous growth in the upstream industrial chain. Affected by the COVID-19 pandemic,IVDThe demand for reagent raw materials has therefore been continuously expanding, from2015year33RMB 10 billion, an increase of2020year1011000 million RMB2015 - 2020The annual compound growth rate for25.2%expected2025The annual market scale will reach2531000 million RMB2020 - 2025The annual compound growth rate for the year will reach20.2%.

chinaIVDReagent Raw Materials Market Scale and Forecast

2015Year to2025Year (estimated)

Data source: Analysis by Frost & Sullivan

mRNAtherapy-Overview of Enzyme Raw Material Market

In China,mRNAThe rise of therapies has driven rapid growth in the upstream enzyme raw material market,2020After the outbreak of the COVID-19 pandemic in 2020, a large number of Chinese companies actively innovated against the novel coronavirusmRNAThe market scale of upstream enzyme raw materials for clinical research has been2020Annual achievement1.5100 billion RMB. In the future,Due tomRNAThe therapy has a wide range of applicable treatment areas, including multiple anti-infective preventive vaccines, tumor immunotherapy, and therapeutic drugs./The vaccine project is already in the R&D and clinical stages, with an expected2025yearmRNAThe market scale of enzyme raw materials required for the therapy will reach14.71000 million RMB.

chinamRNAtherapy-Market scale and forecast of enzyme raw materials

2020Year-end2025Year (estimated)

Data source: Analysis by Frost & Sullivan

Frost & Sullivan integrates the globe.61years of consulting experience,24Frost & Sullivan has been dedicated to serving the booming Chinese market for years, demonstrating a global perspective in helping clients accelerate their business growth and achieve industry-leading benchmarks in terms of growth, innovation, and leadership. The health industry is one of the core areas of focus for Frost & Sullivan. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listings include: Healthyuan (JCARE.SW), Leopu MedicalLEPU.SW), DIngDang Health9886.HK), Baidu Map Suggest (2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leopu Biology2157.HK), Clear Medical1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhuan Cayman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital (2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Medical (9688.HK), OcularViz (1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Geely Pharma1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Biopharmaceuticals2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. In terms of the number of submissions, Frost & Sullivan's healthcare team in Hong Kong is involved inIPO listingMaintain an absolute leading position,2018till2021Year after year, it has always ranked first in market share.

since2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board listed companies, including: Novogene (688428.SH), OPUMAI BIOLOGY688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui Pharmaceutical Health (688046.SH), Haichuang Pharmaceutical688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Medical Group Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.